Renfu Pharmaceuticals: HW231019 tablets enter Phase II clinical trials.

Renfu Pharmaceuticals announced that its holding subsidiary, Yichang Renfu, recently published the registration information for the Phase II clinical trial of HW231019 tablets on the Drug Clinical Trial Registration and Information Disclosure Platform of the National Medical Products Administration. HW231019 tablets are used for a multicenter, randomized, double-blind, parallel, placebo and positive controlled study on the efficacy and safety of postoperative abdominal pain relief. Yichang Renfu has invested approximately RMB 20 million in research and development for this project.